Time-domain A-PPDU for Collision Reduction and Priority Access
This document introduces a Time-domain A-PPDU for IEEE 802.11-24, focusing on collision reduction and priority access for UHR STAs with low latency traffic. The proposal aims to enhance throughput, reduce MPDU loss, and minimize latency through innovative PPDU formatting. By implementing this approach, collision avoidance, priority channel access, and efficient utilization of the wireless medium can be achieved simultaneously.
Uploaded on Mar 04, 2025 | 0 Views
Download Presentation
Please find below an Image/Link to download the presentation.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.If you encounter any issues during the download, it is possible that the publisher has removed the file from their server.
You are allowed to download the files provided on this website for personal or commercial use, subject to the condition that they are used lawfully. All files are the property of their respective owners.
The content on the website is provided AS IS for your information and personal use only. It may not be sold, licensed, or shared on other websites without obtaining consent from the author.
E N D
Presentation Transcript
CATT objectives To determine whether off-lable Avastin works as well as approved medication for neovascular AMD- Lucentis To evaluate how often treatment needs to be given
CATT study patients Single blind 1208 patients 44 centers in U.S. Age > 50 Active CNV (leakage on FA, Fluid within or bellow the retina or bellow RPE on TD-OCT) NO previous treatment for AMD VA 20/25- 20/320
CATT treatment methods 4 treatment groups Avastin as needed Lucentis every 28 days Lucentis as needed Avastin every 28 days first mandatory intravitreal injection 0.50 mg Lucentis 1.25 mg Avastin
CATT treatment methods as needed (signs of CNV) : Leakage on FA Fluid on TD-OCT (within or bellow the retina or bellow RPE) New or persistent hemorrhage Decreased VA (compared with previous) Dye leakage Increased lesion size on FA
CATT Baseline characteristics Mean age : + 80 Sex: + 180 female, + 110 male (every group) Race: + 98% white Lucentis Monthly (n=301) Avastin Monthly (n=286) Avastin PRN (n=300) Lucentis PRN (n=298) Characteristic
CATT Baseline characteristics Lucentis Monthly (n=301) Avastin Monthly (n=286) Avastin PRN (n=300) Lucentis PRN (n=298) Characteristic
CATT main results- Visual acuity Avastin monthly =Lucentis monthly Avastin PRN= Lucentis PRN Avastin PRN? Avastin monthly Avastin PRN? Lucentis monthly Avastin monthly = Lucentis PRN Lucentis PRN= Lucentis monthly
CATT main results Lucentis monthly Avastin monthly Lucentis PRN Avastin PRN Lucentis monthly Avastin monthly Lucentis PRN Avastin PRN
CATT secondary results- Retinal thickness Characteristic Avastin monthly (n= 265) 11.9 + 1.2 Avastin PRN (n=271) 7.7 + 3.5 Pvalue Lucentis monthly Lucentis PRN (n=284) 11.7 + 1.5 (n=285) 6.9 + 3.0 Mean no. of treatments <0.001 Total thickness at fovea- m Mean Mean change at from baseline Retinal thickness plus subfoveal- fluid thickness at fovea- m Mean Mean change at from baseline 226 + 125 300 + 149 -164 + 181 294 + 139 308 + 127 -152 + 178 0.002 0.03 -196 + 176 -168 + 186 152 + 57 172 + 81 -79 + 132 166 + 66 172 + 68 -79 + 123 0.001 0.18 -81 + 134 -100 + 130
CATT secondary results- Retinal fluid Characteristic Avastin monthly (n= 265) Avastin PRN (n=271) Pvalue Lucentis monthly Lucentis PRN (n=284) (n=285) Fluid on optic coherence tomography- no. (%) Absent 69(26.0) 52(19.2) <0.001 124(43.7) 68(23.9) Present 188(70.9) 214(79.0) 203(71.2) 151(53.2) Data missing 9(3.2) 8(3.0) 14(4.9) 5(1.8)
CATT secondary results- Adverse Events Charachretistic Lucentis monthly (n=301) Avastin monthly (n= 286) Lucentis PRN (n=298) Avastin PRN (n=300) Pvalue Between groups groups Among >1 Serious systemic event (MI, Stroke, THI, HTN) 53 (17.6) 64 (22.4) 61 (20.5) 77 (22.7) 0.11 0.04 Gastrointestinal disorder 3 (1.0) 6 (2.1) 2 (0.7) 9 (3.0) 0.11 0.02 Any other system organ class 18 (6.0) 26 (9.1) 16 (5.4) 28 (9.30) 0.14 0.03 Ocular event in the study eye- Endophthalmitis 2 (0.7) 4 (1.4) 0 0 0.03 0.45
CATT summery During 1 Yr period the drugs had equivalent effect on VA PRN dosing results in 4 -5 fewer injections over 1 year than monthly dosing Both drugs reduced fluid in or under the retina. Complete resolution was greater with Lucentis Serious systemic adverse events (primarily hospitalizations) was higher with Avastin than with Lucentis (24.1% vs. 19.0%)
